Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate for Insulin Sensitivity in Overweight/Obese T2DM
NCT00236626Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2000
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Topiramate with Placebo (2 arms). Primary endpoint: Mean change in insulin sensitivity at 9 months. Started Apr 2000; status: completed.
02
Drugs
topiramate
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT00236626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236626.